[1] | Ghafari, M., Hall, M., Golubchik, T., et al. (2024). Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature 626(8001): 1094−1101. DOI: 10.1038/s41586-024-07029-4. |
[2] | DeWolf, S., Laracy, J.C., Perales, M.A., et al. (2022). SARS-CoV-2 in immunocompromised individuals. Immunity 55(10): 1779−1798. DOI: 10.1016/j.immuni.2022.09.006. |
[3] | Lyudovyk, O., Kim, J.Y., Qualls, D., et al. (2022). Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. Cancer Cell 40 (7): 738-753 e735. DOI: 10.1016/j.ccell.2022.05.013. |
[4] | Wang, S.Y., Wang, Y.M., Liu, M., et al. (2023). Migratory pulmonary ground glass opacities caused by SARS-CoV-2 infection in a patient on B-cell depletion therapy. Zhonghua Jie He He Hu Xi Za Zhi 46(12): 1233−1239. DOI: 10.3760/cma.j.cn112147-20230809-00061. |
[5] | Machkovech, H.M., Hahn, A.M., Garonzik Wang, J., et al. (2024). Persistent SARS-CoV-2 infection: Significance and implications. Lancet Infect Dis S 1473-3099(23): 00815−0. DOI: 10.1016/S1473-3099(23)00815-0. |
Xu J., Zhang H., Wang Y., et al., (2024). Chronic active SARS-CoV-2 in B-cell immunodeficiency. The Innovation Medicine 2(2): 100071. https://doi.org/10.59717/j.xinn-med.2024.100071 |
Schematic diagram for chronic active SARS-CoV-2 in B-cell immunodeficiency.